Cats can get diabetes, just like humans – but would you be able to spot the symptoms? Find out what you need to watch out for 👇 #LifeForward #WorldDiabetesDay
Boehringer Ingelheim
İlaç İmalatı
Ingelheim am Rhein, Rhineland-Palatinate 1.870.755 takipçi
Hakkımızda
Our people are our strength. And, together with over 53,000 colleagues, we're creating the next breakthrough in the world of health and innovation for both humans and animals. Are you ready to join us? #LifeForward
- Web Sitesi
-
http://www.boehringer-ingelheim.com
Boehringer Ingelheim için harici link
- Sektör
- İlaç İmalatı
- Şirket büyüklüğü
- 10.001+ çalışan
- Genel Merkez
- Ingelheim am Rhein, Rhineland-Palatinate
- Türü
- Özel Şirket
- Uzmanlık Alanları
- Pharmaceuticals, Animal Health, Innovation, Research, Health Care, Improve Health, Biopharmaceuticals ve Contract Manufacturing
Konum
Boehringer Ingelheim şirketindeki çalışanlar
-
Gwen Whitfield Foster
-
Thomas Macauley
Research Data Management - Lab Services Engineer at Boehringer-Ingelheim
-
Mitchell Taub
Highly Distinguished Research Fellow
-
Ralf Schundelmeier
Innovative Product Leader | Pioneering GenAI-Driven Data, Analytics and Application Platforms | ex Salesforce | HIRING
Güncellemeler
-
#PRESS: We're joining forces with the Mary Tyler Moore Vision Initiative (MTM Vision) to combat vision loss from diabetes. We’re proud to be the first pharmaceutical company to join the MTM Vision Consortium, which aims to unite innovators in the pre-competitive space to address the urgent need for: ➡️ Earlier detection of diabetic retinal disease, including diabetic retinopathy ➡️ Novel treatments that work earlier in disease before vision loss occurs. Find out more about our collaboration and the Consortium: https://lnkd.in/eC99g-5x #RetinalDiseases #EyeHealth
-
Early detection saves lives. This #LungCancerAwarenessMonth, hear from patient advocates as they answer the top questions online about lung cancer diagnosis and the importance of timely access for all. Watch our videos to understand why early screening is crucial. https://lnkd.in/eNEGdW3G #LCAM GO2 for Lung Cancer, WALCE APS, Lung Cancer Europe, Respirando con Valor.
-
-
Driving science forward through collaboration: our new 4SIGHT Network gives retinal health researchers and clinicians access to key elements of our research. That allows us to seamlessly work together and accelerate scientific advances. 4SIGHT is made up of four specialist networks, each focusing on a specific area of retinal health, working towards a common goal: a future of vision preservation and protection for people living with, or at risk of, retinal diseases. Read what members of the network think, below. #RetinalDisease #EyeHealth
-
Obesity is a gateway disease into other cardiovascular, renal, and metabolic diseases. It affects over 1 billion people in the world with numbers continuing to rise. We are working as part of the Innovative Health Initiative (IHI) consortium IMI_SOPHIA to identify biomarkers connected with higher cardiometabolic risk in obesity. Learn more about this groundbreaking research published in Nature Medicine and how this could enable precision prevention of cardiometabolic diseases in people living with obesity: https://rdcu.be/dXXoI #Research #PrecisionMedicine #Obesity
-
-
It’s staggering to think that 1 in 10 people worldwide live with chronic kidney disease (CKD) - but we’re on a mission to prevent disease progression and associated complications. In his latest article, our colleague Sandy Sommer, Head of the Therapeutic Area Cardiovascular, Renal, & Metabolic, shares our vision for the future of CKD care: developing breakthrough treatments that improve the lives of people affected by CKD and connected cardiovascular, renal and metabolic conditions. Discover more here: https://bit.ly/4fiS2vX #LifeForward #ChronicKidneyDisease #KidneyHealth
-
-
He is a Boehringer legend: Michael Mark studied pharmacy in Tübingen, received his PhD and worked as a postdoc – until he decided to switch from academia to the pharmaceutical industry. To us. As the brain behind one of our most important medicines, the pharmacologist remained with our company until his retirement in 2019. A total of 34 years, including 19 years as Head of Cardio-metabolic Diseases Research. To this day, his breakthroughs in pharmaceutical research have shaped and improved the lives of millions of patients 💊 👉🏻 Learn more about Michael's success story in our video: https://lnkd.in/eA4Vu7ds
-
-
Our "Annual Report Magazine" and "Corporate Brand Design Relaunch" won the Red Dot Design Award 2024! Each design work, from concept to execution, is a creative and collaborative journey. Our big thank you goes to the agencies we worked with on these projects - 3st kommunikation and Interbrand. Take a look at the winning publication: https://lnkd.in/e7rsAUv3 #annualreport #reddotaward #designaward
-
We are joining forces with the Broad Institute of MIT and Harvard to address the sleep disturbances that contribute to cognitive impairment. Jointly we will work on treatments to normalize sleeping patterns to bring cognitive and real-world benefits to people with mental health disorders. Learn more: http://bit.ly/4fwXoDT #ResearchCollaboration #Innovation #MentalHealth
-